Pricing Log in Create free account
Saturday 17 October 2026 Export MRK’s income statement to Excel — free account

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.95 0.76 +0.52%
Market cap
$358.2B
P/E
117×
Fwd P/E
53.9×
Dividend yield
2.33%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Merck & Co., Inc. (MRK) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Merck & Co., Inc. (MRK) trades at a EV/Sales of 6.1×. Over the past ten years it has ranged from 3.3× (May 2025) to 6.5× (August 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 4.5× 6.99%
FY2024 4.2× (18.62%)
FY2023 5.2× 4.23%
FY2022 5.0× 12.69%
FY2021 4.4× (14.07%)
FY2020 5.2× (13.84%)
FY2019 6.0× 23.76%
FY2018 4.9× 22.17%
FY2017 4.0× (6.30%)
FY2016 4.2× 9.89%

Quarterly newest first

Period EV/Sales Change
Jun 2026 5.4× 5.51%
Mar 2026 5.1× 13.16%
Dec 2025 4.5× 26.33%
Sep 2025 3.6× 2.19%
42 more quarters

Against its own ten years

Low 3.3× High 6.5×
Ten-year median 4.7×
Current reading's percentile 99

EV/Sales against peers

Company EV/Sales
PFE Pfizer Inc. compare 3.5×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.8×
MRK Merck & Co., Inc. 6.1×
JNJ Johnson & Johnson compare 6.4×
GILD Gilead Sciences, Inc. compare 7.1×
AMGN Amgen Inc. compare 7.3×
ABBV AbbVie Inc. compare 8.8×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on MRK